ESR1 and breast cancer: The binding activity of both conjugates towards ER-α (PDB ID: 4XI3) was reported to be in the same way as bazedoxifene (an FDA-approved drug to treat osteoporosis and breast cancer, Maestro 9.6 software) [131].